Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Downgraded to “Sell” at BidaskClub

BidaskClub downgraded shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) from a hold rating to a sell rating in a research note issued to investors on Friday, July 28th.

Several other brokerages also recently weighed in on INO. Stifel Nicolaus reissued a buy rating and issued a $11.00 price target on shares of Inovio Pharmaceuticals in a report on Thursday, May 25th. Maxim Group set a $12.00 price target on Inovio Pharmaceuticals and gave the stock a buy rating in a report on Thursday, June 8th. HC Wainwright reissued a buy rating and issued a $13.00 price target on shares of Inovio Pharmaceuticals in a report on Friday, June 9th. Aegis raised their price target on Inovio Pharmaceuticals from $11.00 to $14.00 and gave the stock a buy rating in a report on Thursday, May 25th. Finally, Zacks Investment Research raised Inovio Pharmaceuticals from a hold rating to a buy rating and set a $8.75 target price for the company in a report on Tuesday, July 11th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of Buy and an average target price of $20.78.

Shares of Inovio Pharmaceuticals (INO) traded down 3.72% during trading on Friday, reaching $5.43. The company’s stock had a trading volume of 1,361,927 shares. Inovio Pharmaceuticals has a 12-month low of $5.32 and a 12-month high of $9.95. The stock’s market capitalization is $405.22 million. The firm’s 50-day moving average is $7.16 and its 200-day moving average is $6.84.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). The business had revenue of $10.40 million during the quarter, compared to the consensus estimate of $5.83 million. Inovio Pharmaceuticals had a negative return on equity of 65.97% and a negative net margin of 235.91%. The company’s quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter last year, the company earned ($0.11) earnings per share. Equities analysts expect that Inovio Pharmaceuticals will post ($1.07) earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Downgraded to “Sell” at BidaskClub” was first published by BBNS and is the sole property of of BBNS. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://baseballnewssource.com/markets/inovio-pharmaceuticals-inc-nasdaqino-downgraded-by-bidaskclub-updated/1314651.html.

In related news, Director David B. Weiner sold 8,000 shares of Inovio Pharmaceuticals stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $8.00, for a total transaction of $64,000.00. Following the completion of the transaction, the director now directly owns 740,956 shares in the company, valued at $5,927,648. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 10.60% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in INO. Vanguard Group Inc. boosted its position in shares of Inovio Pharmaceuticals by 7.9% in the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock valued at $20,510,000 after buying an additional 226,861 shares in the last quarter. Candriam Luxembourg S.C.A. bought a new position in shares of Inovio Pharmaceuticals during the second quarter valued at $1,411,000. Russell Investments Group Ltd. bought a new position in shares of Inovio Pharmaceuticals during the fourth quarter valued at $559,000. Credit Suisse AG boosted its position in shares of Inovio Pharmaceuticals by 108.6% in the first quarter. Credit Suisse AG now owns 132,688 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 69,068 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Inovio Pharmaceuticals by 12.5% in the first quarter. Geode Capital Management LLC now owns 560,164 shares of the biopharmaceutical company’s stock valued at $3,708,000 after buying an additional 62,045 shares in the last quarter. Institutional investors own 22.92% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns
Darren Daulton Former Catcher with Phillies Dies
Darren Daulton Former Catcher with Phillies Dies


Leave a Reply

 
© 2006-2017 BBNS.